187 related articles for article (PubMed ID: 2787049)
41. [Skeletal distribution and biological markers of Paget's disease].
Meunier PJ; Salson C; Delmas PD
Rev Prat; 1989 Apr; 39(13):1125-8. PubMed ID: 2786643
[TBL] [Abstract][Full Text] [Related]
42. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
[TBL] [Abstract][Full Text] [Related]
43. Clinical value of the measurement of bone remodelling markers in primary hyperparathyroidism.
Minisola S; Scarnecchia L; Carnevale V; Bigi F; Romagnoli E; Pacitti MT; Rosso R; Mazzuoli GF
J Endocrinol Invest; 1989 Sep; 12(8):537-42. PubMed ID: 2592739
[TBL] [Abstract][Full Text] [Related]
44. Two-site enzyme immunoassay for measuring intact human osteocalcin in serum.
Parviainen M; Kuronen I; Kokko H; Lakaniemi M; Savolainen K; Mononen I
J Bone Miner Res; 1994 Mar; 9(3):347-54. PubMed ID: 8191928
[TBL] [Abstract][Full Text] [Related]
45. Serum osteocalcin levels in normal subjects and patients with primary hyperparathyroidism.
Ljunghall S; Hällgren R; Rastad J
Exp Clin Endocrinol; 1985 Dec; 86(2):218-22. PubMed ID: 3879222
[TBL] [Abstract][Full Text] [Related]
46. Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting.
Slovik DM; Gundberg CM; Neer RM; Lian JB
J Clin Endocrinol Metab; 1984 Aug; 59(2):228-30. PubMed ID: 6610686
[TBL] [Abstract][Full Text] [Related]
47. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease.
Seibel MJ; Woitge HW; Pecherstorfer M; Karmatschek M; Horn E; Ludwig H; Armbruster FP; Ziegler R
J Clin Endocrinol Metab; 1996 Sep; 81(9):3289-94. PubMed ID: 8784085
[TBL] [Abstract][Full Text] [Related]
48. Serum osteocalcin radioimmunoassay in bone diseases.
Galli M; Nuti R; Franci B; Righi G; Martorelli MT; Turchetti V; Caniggia M
Ric Clin Lab; 1985; 15(3):253-7. PubMed ID: 3878567
[TBL] [Abstract][Full Text] [Related]
49. [Development of primary hyperparathyroidism in the follow-up of a patient with Paget's disease].
Spivacow FR
Medicina (B Aires); 2009; 69(1 Pt 2):173-6. PubMed ID: 19414302
[TBL] [Abstract][Full Text] [Related]
50. Isotope retention for assessment of bone turnover in involutional osteoporosis.
Passeri M; Palummeri E; Baroni MC; Quaini F; Quintavalla A; Barbagallo M; Franchini D; Ugolotti D
Clin Rheumatol; 1989 Jun; 8 Suppl 2():35-40. PubMed ID: 2788063
[TBL] [Abstract][Full Text] [Related]
51. Plasmatic markers of bone metabolism.
Tamburino G; Fiore CE
Ann Ital Med Int; 1990; 5(3 Pt 3):296-302. PubMed ID: 2081090
[TBL] [Abstract][Full Text] [Related]
52. Changes in plasma bone GLA protein during treatment of bone disease.
Deftos LJ; Parthemore JG; Price PA
Calcif Tissue Int; 1982 Mar; 34(2):121-4. PubMed ID: 6805917
[TBL] [Abstract][Full Text] [Related]
53. Relationship between bone uptake of 99mTc-pyrophosphate and hydroxyproline in blood and urine.
Wiegmann T; Kirsh J; Rosenthall L; Kaye M
J Nucl Med; 1976 Aug; 17(8):711-4. PubMed ID: 180269
[TBL] [Abstract][Full Text] [Related]
54. [Dosage of ionized calcium in osteo-articular pathology].
Eisinger J; Schiano A
Rev Rhum Mal Osteoartic; 1978 Jun; 45(6):423-9. PubMed ID: 684354
[TBL] [Abstract][Full Text] [Related]
55. [Nephrolithiasis and bone involvement in primary hyperparathyroidism. The relative role of vitamin D].
Díez Labajo A; Traba ML; Rapado A; Alvarez Arroyo MV; Peramo B; Díaz Curiel M; de la Piedra C; Calleja JL
Rev Clin Esp; 1992 Mar; 190(5):238-42. PubMed ID: 1579694
[TBL] [Abstract][Full Text] [Related]
56. Treatment of Paget's disease by weekly infusions of 3-aminohydroxypropylidene-1,1-bisphosphonate (APD).
Ryan PJ; Sherry M; Gibson T; Fogelman I
Br J Rheumatol; 1992 Feb; 31(2):97-101. PubMed ID: 1371084
[TBL] [Abstract][Full Text] [Related]
57. Post-partum hypercalcemia in hereditary hyperphosphatasia (juvenile Paget's disease).
Chosich N; Long F; Wong R; Topliss DJ; Stockigt JR
J Endocrinol Invest; 1991; 14(7):591-7. PubMed ID: 1940065
[TBL] [Abstract][Full Text] [Related]
58. Urinary excretion of glycosaminoglycans and hydroxyproline in Paget's disease of bone, compared with neoplastic invasion of bone.
Bower L; Manley G
J Clin Pathol; 1981 Oct; 34(10):1097-101. PubMed ID: 7309892
[TBL] [Abstract][Full Text] [Related]
59. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease.
Duda RJ; O'Brien JF; Katzmann JA; Peterson JM; Mann KG; Riggs BL
J Clin Endocrinol Metab; 1988 May; 66(5):951-7. PubMed ID: 3258870
[TBL] [Abstract][Full Text] [Related]
60. The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.
Reginster JY; Jeugmans-Huynen AM; Wouters M; Sarlet N; McIntyre HD; Franchimont P
Br J Rheumatol; 1992 Jan; 31(1):35-9. PubMed ID: 1730104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
